Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has maintained a Neutral rating on TG Therapeutics (NASDAQ:TGTX) and increased the price target from $12 to $13.
February 29, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on TG Therapeutics, raising the price target from $12 to $13.
The increase in price target by Goldman Sachs suggests a positive outlook on the stock's potential, albeit with a cautious stance. This could lead to a short-term positive sentiment among investors, potentially increasing the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100